1 Introduction The advent of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their combinations, as pharmacological treatments for obesity and type 2 diabetes, has sparked intense debate about their role relative to traditional lifestyle interventions such as exercise and dietary modification
To maintain results, some patients may require ongoing treatment with maintenance injections at regular intervals
Brand-name pens (Ozempic, Wegovy, Mounjaro, Zepbound) undergo extensive stability testing by the manufacturer
Wegovy works by acting like the hormone GLP-1 (glucagon-like peptide-1) which targets areas of the brain that regulate appetite and food intake
Specifically, pH and PO 2 values decreased, whereas PCO 2 , HCT, K + , Cl , and Hb values increased
What to expect : Enhanced confidence and physical mobility, with well-controlled cravings